Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 12/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.64 |
| ▸ | PGR | P06401 | 4/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | SHBG | P04278 | 2/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.59 |
| ▸ | IL6 | P05231 | 1/20 | 0.59 |
| ▸ | GLUL | P15104 | 1/20 | 0.59 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.59 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28809123 | 0.95 | HIF1A (0.66) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| Butyric Acid SCHEMBL27495006 | 0.95 | HIF1A (0.58) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| SCHEMBL6001323 | 0.94 | HIF1A (0.65) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| SCHEMBL141828 | 0.94 | HIF1A (0.62) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| SCHEMBL14931695 | 0.93 | HIF1A (0.64) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| SCHEMBL249836 | 0.93 | HIF1A (0.64) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| SCHEMBL141360 | 0.93 | HIF1A (0.61) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| Water SCHEMBL27961624 | 0.93 | HIF1A (0.61) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| SCHEMBL11238419 | 0.93 | HIF1A (0.63) | HIF1AHSD17B10NR3C1NR3C2PGR | |
| SCHEMBL1535104 | 0.93 | HIF1A (0.63) | HIF1AHSD17B10NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170069-A1 | NANOPREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD AND USE THEREOF | XIANGYA HOSPITAL CENTRAL SOUTH UNIV (CN) | 2025-05-29 | — | — | US | claimed |
| EP-4470532-A1 | NANO PREPARATION FOR JOINT ANALGESIA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Xiangya Hospital, Central South University (CN) | 2024-12-04 | — | — | EP | claimed |
| CN-118662643-A | Application of hormone medicine composition in preparation of medicine for treating osteoarthritis | 中南大学湘雅医院 | 2024-09-20 | — | — | CN | claimed |
| CN-118234515-A | Methods and therapeutic compositions for treating and preventing severe injection site reactions | 腾盛博药生物科技有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-118122163-A | Low shear mixing method for improving stability of external pharmaceutical preparation composition | 江苏知原药业股份有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-116098866-A | Glucocorticoid fat emulsion for treating arthralgia, preparation method and application thereof | 中南大学湘雅医院 | 2023-05-12 | — | — | CN | claimed |
| CN-116077669-A | Glucocorticoid nano-lipid carrier for treating arthralgia, preparation method and application thereof | 中南大学湘雅医院 | 2023-05-09 | — | — | CN | claimed |
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | claimed |
| CN-113332439-A | Methods of treatment and compositions comprising dual PI3K delta-gamma kinase inhibitors and corticosteroids | 理森制药股份公司 | 2021-09-03 | — | — | CN | claimed |
| CN-107613985-B | Aqueous suspensions of nanoparticles containing glucocorticoids | 株式会社活效制药 | 2021-05-25 | — | — | CN | claimed |
| WO-2006092374-A1 | ANTIFUNGAL COMPOSITIONS COMPRISING SERTACONAZOL AND HYDROCORTISONE AND/OR AN ANTIBACTERIAL QUINOLONE COMPOUND | FERRER INTERNACIONAL, S. A. (ES) | 2006-09-08 | — | — | WO | claimed |
| EP-1698336-A1 | Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent | FERRER INTERNACIONAL, S.A. (ES) | 2006-09-06 | — | — | EP | claimed |
| EP-1633368-A2 | FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER | STIEFEL LABORATORIES, INC. (US) | 2006-03-15 | — | — | EP | claimed |
| US-6890544-B2 | Gel composition for the topical treatment of poison ivy and other forms of contact dermatitis | MCCADDEN MICHAEL E (US) | 2005-05-10 | — | — | US | claimed |
| WO-2004105702-A2 | FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER | STIEFEL LABORATORIES, INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-20040241099-A1 | Foamable pharmaceutical compositions and methods for treating a disorder | CONNETICS CORPORATION | 2004-12-02 | — | — | US | claimed |
| US-20030232086-A1 | Gel composition for the topical treatment of rashes, dermatoses and lesions | MCCADDEN MICHAEL E (US) | 2003-12-18 | — | — | US | claimed |
| US-6656928-B1 | Composition for the topical treatment of rashes, dermatoses and lesions | MCCADDEN MICHAEL E (US) | 2003-12-02 | — | — | US | claimed |
| US-20030077304-A1 | Gel composition for the topical treatment of poison ivy and other forms of contact dermatitis | MCCADDEN MICHAEL E (US) | 2003-04-24 | — | — | US | claimed |
| US-6479058-B1 | Composition for the topical treatment of poison ivy and other forms of contact dermatitis | MCCADDEN MICHAEL E (US) | 2002-11-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040241099-A1 | Foamable pharmaceutical compositions and methods for treating a disorder | CLN6, CYP27A1, CYP46A1 | HIF1A 3815/4885HSD17B10 289/4885NR3C1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.